RxDoctor Payments Data

Andy Abril, MD

Rheumatology · Jacksonville, FLNPI 1447240239

Payments from drug & device makers

$222,736in general payments, 2019–2025

Across 78 payments — averaging $2855.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$75K
  • Boehringer Ingelheim$50K
  • AstraZeneca$45K
  • Hoffmann-la Roche Limited$41K
  • Boehringer Ingelheim International GmbH$7K
  • AbbVie$2K
  • plus $3K from 8 others

What the payments were for

  • Consulting fees$12,94062%
  • Speaking & faculty fees$3,52917%
  • Travel & lodging$1,3456%
  • Food & beverage$3,17615%
  • Education$10%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$222,736 in reported general payments places this provider in the 80th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$181,067
Medicare patients
414
Services billed
26,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab12$141,459
Enbrel SureclickEtanercept16$137,262
Humira(Cf) PenAdalimumab11$110,277
RinvoqUpadacitinib13$85,214
Cimzia (2 Pack)Certolizumab Pegol12$76,516
ActemraTocilizumab13$65,521
Mycophenolate Mofetil41$8,887
MethotrexateMethotrexate Sodium92$3,503
Hydroxychloroquine Sulfate62$2,555
Prednisone144$1,332
Folic Acid33$483
Methylprednisolone18$270
Allopurinol11$60

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$2,039$85,21413 claims
Genentech, Inc.Actemra$453$65,52113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 453 rheumatology providers in Florida.

Other rheumatology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →